A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

19992,092 citationsJournal Articlebronze Open Access

Authors

Michael E. Weinblatt · Brigham and Women's Hospital

Joel M. Kremer

Arthur D. Bankhurst · University of New Mexico

Ken J. Bulpitt · University of California, Los Angeles

Roy Fleischmann · Metroplex Clinical Research Center

Robert I. Fox · Scripps Clinic

Christopher G. Jackson · University of Utah

Abstract

In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than methotrexate alone.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Toxin Mechanisms and Immunotoxins Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 340, Issue 4, pp. 253-259

DOI: 10.1056/nejm199901283400401

Field-Weighted Citation Impact: 102.07